

Oxbryta (voxelotor)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Sickle cell disease (SCD) is a genetic disorder that affects the structure and function of red blood cells. In SCD, the body produces an abnormal form of hemoglobin, the protein in red blood cells that carries oxygen to the body's tissues. The underlying cause of SCD is a specific mutation in the beta globin gene, known as HbS, which results in the production of abnormal hemoglobin. This abnormal hemoglobin causes red blood cells to become stiff and sticky, forming a sickle or crescent shape. These sickle-shaped cells can block blood flow in small blood vessels, causing pain, tissue damage, and a variety of complications.

In all forms of SCD, at least one copy of the beta globin gene has the HbS mutation. The most common form of SCD is sickle cell anemia (HbSS), where both copies of the beta-globin genes have the HbS mutation. Other forms of SCD can result from a combination of the HbS mutation with other mutations in hemoglobin genes. SCD is most commonly found in people of African descent, but it also occurs in people of Hispanic, Middle Eastern, and Mediterranean descent.

Symptoms of SCD can vary widely, but common complications include acute and chronic pain, infections, organ damage, and stroke. Treatment for SCD generally focuses on managing symptoms and

preventing complications. This can include medications to manage pain and prevent infections, blood transfusions to increase oxygen supply to tissues, and bone marrow transplants in severe cases.

There are several drugs available to treat SCD. These include:

- Hydroxyurea: This medication is an oral chemotherapy drug that can increase the production of fetal hemoglobin, a type of hemoglobin that is not affected by the sickle cell mutation. By increasing the amount of fetal hemoglobin, hydroxyurea can help prevent sickling and reduce complications of SCD. It is typically used for people with moderate to severe disease.
- L-glutamine oral powder: This medication is a prescription powder that is taken orally to reduce the acute complications of sickle cell disease. It is approved for use in people with SCD who are 5 years of age and older.
- Voxelotor: This medication is an oral medication that can increase the oxygen-carrying capacity of hemoglobin, reducing sickling and improving oxygen delivery to tissues. It is approved for use in people with SCD who are 4 years of age and older.
- Crizanlizumab: This medication is an intravenous infusion that can reduce the frequency of pain crises in people with SCD. It works by blocking a molecule called P-selectin, which is involved in the adhesion of sickle cells to blood vessel walls. It is approved for use in people with SCD who are 16 years of age and older.

Definitions

"Beta-globin gene" is a subunit of hemoglobin that is essential for carrying oxygen to the body.

"Beta-thalassemia trait" is an inherited blood disorder in which the body does not make hemoglobin (hgb) normally.

"Capillary beds" are a network of tiny branching blood vessels that form between the arteries and veins.

"Hemoglobin (Hgb)" is a protein inside red blood cells that carries oxygen from the lungs to the rest of the body.

"Red blood cells (RBCs)" are blood cells that contain hemoglobin (Hgb).

"Reticulocyte" is a red blood cell that is still developing.

"Sickle Cell Disease (SCD)" is a group of inherited red blood cells (RBCs) disorders.

“Sickled red blood cell” is when a red blood cell (RBC) becomes hard and sticky and looks like a C-shape.

“VOC or Vaso-occlusive crisis” is when sickled blood cells block blood flow to the point that tissues become deprived of oxygen causing pain and/or organ dysfunction that requires urgent treatment.

Medical Necessity Criteria for Initial Authorization

The Plan considers **Oxbryta (voxelotor)** medically necessary when ALL of the following criteria are met:

1. The medication is being prescribed by or in consultation with a specialist with expertise in the diagnosis and management of sickle cell disease; **AND**
2. The member is 4 years of age or older; **AND**
3. The member has a confirmed diagnosis of sickle cell disease AND BOTH of the following:
 - a. The member has previously experienced 1 or more sickle cell-related vaso-occlusive crisis within the previous 12 months; **and**
 - b. The member’s baseline hemoglobin (Hgb) is between 5.5 and 10.5 g/dL; **AND**
4. The member has documentation of ONE of the following:
 - a. is being currently treated with and will continue treatment with hydroxyurea in conjunction with Oxbryta (voxelotor); **or**
 - b. is unable to use, or has tried and failed hydroxyurea therapy; **AND**
5. Oxbryta (voxelotor) will not be used concomitantly with Adakveo (crizanlizumab); **AND**
6. Oxbryta (voxelotor) is being prescribed within the manufacturer’s published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; **AND**
7. Chart documentation and supporting laboratory test results are provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met, Oxbryta (voxelotor) will be approved for 12 months.

Medical Necessity Criteria for Reauthorization

Reauthorization for 12 months will be granted for members 4 years of age or older with a confirmed diagnosis of sickle cell disease when chart documentation is provided showing ALL of the following criteria are met:

1. The member’s condition has improved on Oxbryta treatment as demonstrated by at least ONE of the following:
 - a. The member has an increase in hemoglobin (Hgb) by ≥ 1 g/dL from baseline; **or**

- b. The member has a decrease in indirect bilirubin from baseline; **or**
 - c. The member has a decrease in percent reticulocyte count from baseline; **or**
 - d. The member has experienced a reduction in sickle cell-related vaso-occlusive crisis;
- AND**
- 2. The member is currently receiving hydroxyurea OR the member is unable to use or has tried and failed hydroxyurea therapy; **AND**
 - 3. Oxbryta (voxelotor) will not be used concomitantly with Adakveo (crizanlizumab); **AND**
 - 4. Oxbryta (voxelotor) is being prescribed within the manufacturer’s published dosing guidelines or falls within dosing guidelines found in a compendia of current literature.

Table 1: Oxbryta (voxelotor) Recommended Dosage

Use in Specific Populations	12 Years and Older	4 Years to Less Than 12 Years		
		10 kg to less than 20 kg	20 kg to less than 40 kg	40 kg or greater
without severe hepatic impairment	1,500 mg orally once daily	600 mg	900 mg	1,500 mg
with severe hepatic impairment (Child Pugh C)	1,000 mg orally once daily	1,000 mg (two 500 mg tablets) or 900 mg (three 300 mg tablets for oral suspension or three 300 mg tablets)	600 mg	300 mg
Concomitant Use of Strong CYP3A4 Inducer	2,500 mg orally once daily	900 mg	1,500 mg	2,500 mg (five 500 mg tablets) or 2,400 mg (eight 300 mg tablets for oral suspension or eight 300 mg tablets)
Concomitant Use of Moderate CYP3A4 Inducers	2,000 mg orally once daily	900 mg	1,200 mg	2,000 mg (four 500 mg tablets) or 2,100 mg (seven 300 mg tablets for oral suspension or seven 300 mg tablets)

Experimental or Investigational / Not Medically Necessary

Oxbryta (voxelotor) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

References

1. Adakveo (crizanlizumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2022.
2. Brandow AM et al: American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv.* 4(12):2656-701, 2020
3. Brawley O, Cornelius L, Edwards L et al. National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease. *Ann Intern Med.* 2008;148(12):932. Doi:10.7326/0003-4819-148-12-200806170-002200.
4. Chou ST et al: American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv.* 4(2):327-55, 2020
5. Endari (glutamine) [prescribing information]. Torrance, CA: Emmaus Medical, Inc; October 2020.
6. Howard J et al: Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Haematol.* 8(5):e323-33, 2021
7. Liem RI et al: American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood Adv.* 3(23):3867-97, 2019
8. National Heart, Lung, and Blood Institute: Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. NHLBI website. Published 2014. Accessed February 22, 2023. <https://www-nhlbi-nih-gov.libproxy.unm.edu/health-topics/evidence-based-management-sickle-cell-disease>
9. Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics Inc; October 2022.
10. Saunthararajah Y et al: Sickle cell disease: clinical features and management. In: Hoffman R et al, eds: *Hematology: Basic Principles and Practice.* 7th ed. Elsevier; 2018:584-607
11. Siklos (hydroxyurea) [prescribing information]. Rosemont, PA: Medunik USA Inc; December 2021.
12. US Food and Drug Administration: FDA Approves Voxelotor for Sickle Cell Disease. FDA website. Updated November 25, 2019. Accessed February 22, 2023. <https://www-fda-gov.libproxy.unm.edu/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease>
13. Vichinsky E, Hoppe C, Ataga K et al. A phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. *New England Journal of Medicine.* 2019;381(6):509-519. Doi:10.1056/nejmoa1903212.
14. Yawn BP et al: Management of sickle cell disease: recommendations from the 2014 expert panel report. *Am Fam Physician.* 92(12):1069-76, 2015

Clinical Guideline Revision / History Information

Original Date: 03/17/2022

Reviewed/Revised: 3/23/2023